EA-230

DB19114InvestigationalSmall molecule

EA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).

Chemical structure of EA-230
Formula / weight
C15H27N5O6 · 373.41 g/mol (avg)
Also known as
(2S)-2-((2-(((2S)-5-AMINO-2-(((2S)-2-AMINOPROPANOYL)AMINO)-5-OXO-PENTANOYL)AMINO)ACETYL)AMINO)-3-METHYL-BUTANOIC ACID · L-valine, l-alanyl-l-glutaminylglycyl-
Code names
AQGV · EA-230 · NMPF-46

Resolves to

Compound
UNIIEJB8KD4JLLCAS503844-09-5ChEMBLCHEMBL4802142
Structure
InChIKeyDXRXYJYFADHAPA-AUTRQRHGSA-NSMILESCC(C)[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N)C(O)=O

What you can answer from here — as of January 28, 2026

3Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of EA-230, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In